Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
β-interferon topical treatment in low and high risk cervical lesions
Show Less
1
Service of Gynecologic Oncology, and Cytodiagnostics, Institute of Gynecology, Padua University (Italy)
Clin. Exp. Obstet. Gynecol. 1991, 18(2), 91–97;
Published: 10 June 1991
Abstract
In a series of 131 patients we evaluated the effects of medical therapy with beta-Interferon cream in patients with cervical Human Papilloma Virus (HPV) infection, which in some cases, was associated with CIN. Treatment consisted of the direct daily application of 1,000,000 IU β-Interferon cream to colposcopically positive areas over a period of 15 days. At intervals of 1, 6, 12 and 24 months following treatment, cytohistological tests were carried out to assess the effects of treatment. At the 24-month control, the overall percentage for regression was 79.57% of cases. Regression was observed in 58.33% of patients with cytohistological changes associated with HPV without atypia, and in 69.85% of patients with HPV with atypia (38.9% total regression). The regression pattern for CIN lesions was as follows: in CIN lesions, regression occurred in 85.36%, in CIN II in 84.20%, and 37.5% of CIN III cases showed total regression.